trial · primary record
pembrolizumab
Hodgkin Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 27 |
| Primary completion | 2025-08-31 |
| Primary endpoint | Response using Lugano Criteria |
| Registry ID | NCT03331731 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:25.169Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03331731
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pembrolizumab · approval
- Pembrolizumab · compound